These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15497929)

  • 1. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
    Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
    Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours.
    Kolomecki K; Stepien H; Bartos M; Kuzdak K
    Endocr Regul; 2001 Mar; 35(1):9-16. PubMed ID: 11308991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
    Pancewicz SA; Izycka A; Klibingat M; Zajkowska JM; Swierzbińska-Pijanowska R; Kondrusik M; Grygorczuk SS; Izycki T; Hermanowska-Szpakowicz T
    Pol Merkur Lekarski; 2008 Dec; 25(150):495-9. PubMed ID: 19205380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
    Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
    Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
    Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
    Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
    J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
    Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
    Vasala K; Turpeenniemi-Hujanen T
    Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer.
    Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
    Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
    Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
    Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ratio of metalloproteinase 2 to tissue inhibitor of metalloproteinase 2 in medullary thyroid carcinoma.
    Cavalheiro BG; Junqueira CR; Brandão LG
    Arch Otolaryngol Head Neck Surg; 2009 Aug; 135(8):812-7. PubMed ID: 19687404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.